IVF
INVO Fertility, Inc.
There isn't enough reported data to score IVF yet.
IVF Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Weak | |
| Unavailable |
IVF's revenue is currently healthy, but its profitability and cash flow are under pressure. There isn't enough data to rate its balance sheet.
IVF PE Valuation
IVF has no meaningful PE right now: it lost money over the past year.
IVF Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Growth | |
| -- | |
| Limited | |
| -- |
Analysts expect IVF's losses to shrink, with revenue growing.
IVF Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2023 | -$284,774.40 | +$30,193.92 |
| Q2 2023 | -$365,414.40 | -$36,622.08 |
| Q1 2023 | -$400,896.00 | -$99,751.68 |
| Q4 2022 | -$414,720.00 | -$104,359.68 |
| Q3 2022 | -$314,968.32 | +$353,191.68 |
| Q2 2022 | -$328,792.32 | +$394,663.68 |
| Q1 2022 | -$301,144.32 | +$469,313.28 |
| Q4 2021 | -$310,360.32 | +$492,353.28 |
IVF is still losing money, but far less than before: $284,774.40 per share over the past year, against $802,713.60 at its worst in late 2020.
IVF Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $2.2M | +17% |
| Q1 2026 | $2M | +23% |
| Q4 2025 | $1.6M | -7.7% |
| Q3 2025 | $1.8M | +23% |
| Q2 2025 | $1.9M | +1.5% |
| Q1 2025 | $1.6M | +3.9% |
| Q4 2024 | $1.7M | +24% |
| Q3 2024 | $1.4M | +47% |
IVF's revenue is recovering but still below its 2021 peak: $2M last quarter, up 17% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -59% | +101 points |
| Q1 2026 | -79% | +966 points |
| Q4 2025 | -89% | +143 points |
| Q3 2025 | -93% | -2.3 points |
| Q2 2025 | -160% | -57 points |
| Q1 2025 | -1045% | -985 points |
| Q4 2024 | -232% | -123 points |
| Q3 2024 | -91% | +0.2 points |
IVF's operating margin was −59% last quarter, up 101 points from the same quarter a year ago, near the top of its range since 2019.
IVF Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | $13.4K | +$709.6K |
| Q3 2025 | -$1.8M | -$1.1M |
| Q2 2025 | -$1.7M | -$215.7K |
| Q1 2025 | -$3.6M | -$3.2M |
| Q4 2024 | -$696.3K | +$93.6K |
| Q3 2024 | -$640.8K | +$714.7K |
| Q4 2023 | -$789.9K | +$214.1K |
| Q3 2023 | -$1.4M | +$295.3K |
IVF has burned cash in almost every quarter: −$7M over the past year, against −$3M the year before.
IVF Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -14% | -103 shares |
| 1 year | +276% | +456 shares |
| 3 years | +2288% | +595 shares |
| 5 years | +5545% | +610 shares |
IVF has 621 diluted shares, up 276% from a year ago.
IVF Net Leverage
IVF's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
IVF Weekly Momentum
As of the close on Nov 12, 2026: $2.69.
IVF PE vs Healthcare Sector
IVF has no meaningful PE right now: it lost money over the past year.
IVF Weekly Moving Averages
As of the close on Nov 12, 2026: $2.69.
IVF Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2026 YTD | $3.42 | $2.69 | -21% |
It's down 21% so far in 2026.